Search clinical trials for: Amikacin Inhalation Dry Powder

Total 323 results

University Medical Center Groningen

Recruiting

Pharmacokinetic Evaluation and Local Tolerability of Dry Powder Amikacin Via the Cyclops™

Tuberculosis

Netherlands
AlgiPharma AS
Imperial College London; Cystic Fibrosis Foundation; University Hospital of Cologne and other collaborators

Withdrawn

A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis (SMR3372)

Cystic Fibrosis

Germany
Insmed Incorporated

Completed

A Study to Investigate Lung Deposition of Inhaled Amikacin-loaded Liposomes in Healthy Male Participants

Healthy Volunteers
Insmed Incorporated

Withdrawn

Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa

Cystic Fibrosis
Chiesi Farmaceutici S.p.A.

Completed

Study to Investigate the Pharmacokinetics of CHF 6001 DPI Administered Via Nexthaler® Device or the Capsule for Oral Inhalation Via Aerolizer® Device

COPD

Belgium
Insmed Incorporated
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria

Mycobacterium Infections, Nontuberculous

United States, Canada
Insmed Incorporated

Completed

Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone (CONVERT)

Mycobacterium Infections, Nontuberculous
Cardeas Pharma

Withdrawn

Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative and / or Gram-positive Bacterial Colonization

Pneumonia, Bacterial
Cardeas Pharma

Completed

Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia (IASIS)

Pneumonia, Bacterial

Spain, United States, Greece, Hungary, Turkey, Puerto Rico, France
Insmed Incorporated

Completed

Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection

Cystic Fibrosis

France, Poland, United Kingdom, Germany, Spain, Belgium, Bulgaria, Serbia, Denmark, Greece, Netherlands, Hungary, Ireland, Slovakia, Canada, Italy, Austria
Insmed Incorporated

Completed

Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase

Cystic Fibrosis

Poland, Ukraine, Serbia, Belgium, Hungary, Slovakia, North Macedonia
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

Asthma | Chronic Obstructive Pulmonary Disease COPD

United States
Mannkind Corporation

Completed

A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males

Diabetes Mellitus, Type 2 | Healthy Males

Netherlands
Respira Therapeutics, Inc.

Completed

A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Australia
Mannkind Corporation

Completed

Comparison of 30 Units of TI (Technosphere® Insulin) Prepared With Insulin From Two Different Suppliers

Healthy Volunteers

United States
Insmed Incorporated

Completed

Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)

Cystic Fibrosis

Poland, Ukraine, Serbia, Belgium, Hungary, Slovakia, North Macedonia
Respira Therapeutics, Inc.

Completed

A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234

Healthy Volunteer

Australia
GlaxoSmithKline

Completed

Long-term Safety Study for GSK573719/GW642444 in Japanese (DB2115362)

Pulmonary Disease, Chronic Obstructive

Japan
Bayer
Nektar Therapeutics

Completed

Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-ventilated Patients With Nosocomial Pneumonia

Pneumonia

United States, France
GlaxoSmithKline

Completed

Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Romania, Russian Federation, Ukraine, Argentina, Poland, Czechia
GlaxoSmithKline

Completed

A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Russian Federation, Chile, Poland, Mexico, Estonia, Korea, Republic of, Philippines
Bayer
Nektar Therapeutics

Completed

Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia (INHALE 1)

Pneumonia, Bacterial

Korea, Republic of, Taiwan, United States, Canada, Philippines, Turkey, Thailand, Australia, Mexico, Colombia, Czechia, Brazil
Mannkind Corporation

Completed

A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Netherlands
GlaxoSmithKline

Completed

Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

Asthma

United States, Germany, Japan, Romania, Russian Federation, Poland
Esfam Biotech Pty Ltd

Not yet recruiting

A Dose Escalation Phase 1 Study Evaluating the Safety and Pharmacokinetics of an Inhaled COVID-19 Inhibitor Delcetravir in Healthy Subjects

COVID-19
Theravance Biopharma
GlaxoSmithKline; Hammersmith Medicines Research

Completed

A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects

Pulmonary Disease, Chronic Obstructive

United Kingdom
Orion Corporation, Orion Pharma

Completed

Inspiratory Flow Parameters and Handling of Easyhaler and Turbuhaler Inhalers (PIFECO)

Pulmonary Disease, Chronic Obstructive | Asthma

United Kingdom, Finland
Vectura Limited
UCB Pharma

Completed

An Evaluation of VR942 in Healthy Volunteers and Patients With Mild Asthma

Asthma

United Kingdom
Savara Inc.

Completed

AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis

Cystic Fibrosis | MRSA

United States, Canada
Mannkind Corporation

No longer available

Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder

Type 1 Diabetes | Type 2 Diabetes

United States
GlaxoSmithKline

Completed

Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

Asthma

United States, Germany, Japan, Romania, Ukraine, Poland
GB002, Inc.

Not yet recruiting

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

Pulmonary Arterial Hypertension

United States
Savara Inc.
Cystic Fibrosis Foundation; Synteract, Inc.

Completed

Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients

Cystic Fibrosis

United States
Insmed Incorporated

Completed

Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212

NTM Lung Infection Due to MAC
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Australia, Germany, Estonia, Chile, Netherlands, Peru, South Africa, Sweden, Mexico, United Kingdom, Italy, Philippines, Canada
GB002, Inc.

Recruiting

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

Pulmonary Arterial Hypertension

United States, Spain, Israel, Korea, Republic of, Netherlands, France, Singapore, United Kingdom, Lithuania, Australia, Latvia, Argentina, Portugal, Greece, Czechia, Puerto Rico, Belgium, Italy, Poland, Romania, Serbia, Austria, Chile, Denma... and more
GB002, Inc., a wholly owned subsidiary of Gossamer...

Recruiting

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

United States, Australia, Spain, Czechia, France, Germany, United Kingdom, Belgium
GB002, Inc., a wholly owned subsidiary of Gossamer...

Completed

Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

United States, United Kingdom
GlaxoSmithKline

Completed

A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Australia, Argentina, Germany, Spain, South Africa, Mexico, Peru, Netherlands, Canada, United Kingdom, Denmark, Chile, Italy, Sweden
GB002, Inc., a wholly owned subsidiary of Gossamer...

Completed

GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

Pulmonary Artery Hypertension

United States, Spain, Australia, Germany, Serbia, Czechia, Belgium, Canada, Austria, France, United Kingdom
Insmed Incorporated

Completed

Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections

Pseudomonas Aeruginosa Infection

France, Poland, United Kingdom, Germany, Spain, Belgium, Bulgaria, Denmark, Greece, Canada, Netherlands, Hungary, Italy, Ireland, Sweden, Slovakia, Austria, Serbia
GB002, Inc., a wholly owned subsidiary of Gossamer...
Worldwide Clinical Trials; Pulmokine Inc.

Completed

Phase 1A Safety Trial of Inhaled PK10571 (GB002)

Safety Issues

United States
Biota Scientific Management Pty Ltd
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

CS-8958 Single Inhaled Dose in Elderly

Influenza

United Kingdom
Biota Scientific Management Pty Ltd
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety, Tolerability and Pharmacokinetic Study of Biota-CS-8958

Influenza

United Kingdom
Ansun Biopharma, Inc.

Completed

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen (DAS181-2-05)

Parainfluenza

United States
Hiroshima University
Agricultural Producers' Cooperative Corporation Shinpo-en

Completed

Effects of Blueberry Dry Powder on Glycemic Status in Subjects With Prediabetes

Prediabetes

Japan
Novartis Pharmaceuticals

Completed

Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon Devices

Asthma

Germany, Netherlands, United Kingdom
Mannkind Corporation

Terminated

Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

United States
Pharmaxis

Completed

Crossover Trial Determining the Efficacy of Dry Powder Mannitol to Improve Lung Function in Subjects Aged 6-17 Years

Cystic Fibrosis

United Kingdom
Insmed Incorporated

Completed

Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex (ARISE)

Mycobacterium Infections, Nontuberculous

United States, Argentina, Australia, Austria, Canada, Chile, Denmark, Germany, Israel, Italy, Korea, Republic of, New Zealand, Spain, Taiwan

Search clinical trials for: Amikacin Inhalation Dry Powder

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations